Business Context and Reporting Period
This Form 8-K Current Report was filed by Inogen, Inc. on February 16, 2021, covering events occurring on February 12 and February 13, 2021. The filing addresses changes to the Company's Board of Directors, specifically the resignation of a director and the appointment of a new director.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Resignation: Scott Beardsley resigned as a member of the Board of Directors, the Compensation Committee, and the Nominating and Governance Committee, effective immediately on February 12, 2021. The resignation was not due to any disagreement with the Company.
- Appointment: Kristen Miranda was appointed to the Board of Directors, effective March 1, 2021. She will serve as a Class I director and a member of the Compensation Committee.
Management Commentary, Risks, and Unusual Items
Director Background: The Board appointed Ms. Miranda due to her extensive healthcare leadership experience, including roles as Aetna's West Region President and previous senior positions at Agilon Health, Blue Shield of California, Wellpoint, and CIGNA.
Compensation Arrangements: Ms. Miranda's compensation includes:
- Cash fees of $45,000 per year for Board service and $7,500 per year for Compensation Committee service, paid quarterly in arrears on a pro-rata basis.
- An initial award of 1,135 restricted stock units (RSUs) vesting on the earlier of May 11, 2021, or the day prior to the next annual meeting of stockholders.
Risks and Contingencies: The filing states there are no family relationships between Ms. Miranda and other directors or officers, and no undisclosed transactions exist. No specific financial risks or contingencies are disclosed in this report.
Investor Verification Checklist
- Verify the effective date of Kristen Miranda's Board appointment (March 1, 2021) and her specific committee assignments.
- Confirm the vesting schedule for the 1,135 RSUs granted to Ms. Miranda.
- Review the Company's outside director compensation policy to understand the pro-rata payment structure for the partial year.
- Check subsequent filings for the impact of this board composition change on future strategic decisions.